Sema4|GeneDx to Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study.  Learn more >>

Breast/Gyn Cancer Panel

New York
Approved


Genes

ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FANCC, FANCM, MLH1, MSH2, MSH6, MUTYH, NF1, PALB2, PMS2, POLD1, PTEN, RAD51C, RAD51D, RECQL, STK11, TP53

Conditions

  • Breast Cancer
  • Endometrial Cancer
  • Ovarian Cancer

Clinical Utility

  • Breast or endometrial (uterine) cancer diagnosed under 50 years of age
  • Multiple cancers in one person, either of the same origin (such as two separate breast cancers) or of different origins (such as breast cancer and ovarian cancer or endometrial and colon cancer)
  • Ovarian cancer or male breast cancer at any age
  • Multiple relatives diagnosed with the same or related cancers (including breast, ovarian, endometrial, pancreatic and/or prostate) on the same side of the family and spanning multiple generations
  • Ashkenazi Jewish ancestry with a history of breast, ovarian or pancreatic cancer

Lab Method

  • Deletion/Duplication Analysis
  • Next-Gen Sequencing

Test Code

B273

CPT Codes*

81432x1, 81433x1

ABN Required

No

Turnaround Time**

2 weeks

Preferred Specimen

2-5 mL Blood - Lavender Top Tube

Alternative Specimen

Buccal Swabs | Fibroblasts (separate charge for cell culture may apply)

*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

**Reporting times are typical and begin once the sample(s) are received at the GeneDx laboratory, but could be extended in situations outside GeneDx’s reasonable control.